SLS vs. AFMD, VTVT, CUE, ASMB, RLYB, BTAI, JAGX, HOOK, TPST, and SCYX
Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Affimed (AFMD), vTv Therapeutics (VTVT), Cue Biopharma (CUE), Assembly Biosciences (ASMB), Rallybio (RLYB), BioXcel Therapeutics (BTAI), Jaguar Health (JAGX), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
SELLAS Life Sciences Group has a net margin of 0.00% compared to SELLAS Life Sciences Group's net margin of -1,280.27%. SELLAS Life Sciences Group's return on equity of -118.17% beat Affimed's return on equity.
Affimed received 420 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 58.82% of users gave SELLAS Life Sciences Group an outperform vote.
Affimed has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500.
SELLAS Life Sciences Group has lower revenue, but higher earnings than Affimed. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Affimed and Affimed both had 5 articles in the media. Affimed's average media sentiment score of 0.76 beat SELLAS Life Sciences Group's score of 0.70 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.
30.8% of Affimed shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 1.6% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Affimed presently has a consensus target price of $45.00, indicating a potential upside of 757.14%. SELLAS Life Sciences Group has a consensus target price of $3.00, indicating a potential upside of 105.48%. Given SELLAS Life Sciences Group's higher possible upside, equities research analysts clearly believe Affimed is more favorable than SELLAS Life Sciences Group.
Summary
Affimed beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.
Get SELLAS Life Sciences Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SELLAS Life Sciences Group Competitors List
Related Companies and Tools
